Siegel D, Lopez J, Meier J
Medical Service, Department of Veterans Affairs, Northern California Health Care System, Martinez 94553, USA.
Am J Hypertens. 1998 Nov;11(11 Pt 1):1271-8. doi: 10.1016/s0895-7061(98)00158-7.
Patterns of antihypertensive drug use, the cost of this care and potential savings with changes of treatment patterns, were studied for all hypertensives treated at US Veterans Affairs (VA) medical facilities for fiscal years 1995 and 1996. Data was aggregated by individual medication as well as by antihypertensive drug class. Cost estimates were based on median cost and number of units for each dosage form of each medication dispensed at all facilities. Potential savings were estimated by substituting beta-blockers or diuretics for calcium antagonists. In a subset of patients the prevalence of hypertension, and among hypertensives the prevalence of coronary artery disease, congestive heart failure, and diabetes mellitus, was determined. For these patients, patterns of treatment by antihypertensive drug class was examined. For all VA facilities, of the 10 most frequently prescribed antihypertensives in 1995, four were calcium antagonists, two angiotensin converting enzyme (ACE) inhibitors, two beta-blockers, and two diuretics. In 1996, this was changed by the addition of an ACE inhibitor and the subtraction of a diuretic combination. Calcium antagonists accounted for 37% of treatment days in 1995 and 35% in 1996, ACE inhibitor use went from 34% to 36%, beta-blockers from 17% to 18%, and diuretic use remained at 12%. In 1996, approximately 86.6 million dollars were spent on calcium antagonists, 51.8 million on ACE inhibitors, 7.9 million on beta-blockers, and 3.6 million on diuretics. The estimated annual cost savings for each 1% conversion of calcium antagonists to beta-blockers would be $713,000 and to diuretics $758,000. In a subset of 7526 hypertensive patients with known comorbid conditions, calcium antagonists and ACE inhibitors were also the most commonly used drug classes for all categories of patients, including those without coronary artery disease, congestive heart failure, and diabetes mellitus. Calcium antagonists and ACE inhibitors were the most commonly dispensed antihypertensives at VA facilities for both 1995 and 1996, with a small decrease in calcium antagonist use from 1995 to 1996. The cost implications of these practice patterns as compared with the primary use of diuretics and beta-blockers are enormous.
对1995财年和1996财年在美国退伍军人事务部(VA)医疗设施接受治疗的所有高血压患者的抗高血压药物使用模式、这种治疗的成本以及治疗模式改变可能带来的节省进行了研究。数据按个体药物以及抗高血压药物类别进行汇总。成本估计基于所有设施中每种药物每种剂型的中位数成本和单位数量。通过用β受体阻滞剂或利尿剂替代钙拮抗剂来估计潜在节省。在一部分患者中,确定了高血压的患病率,以及高血压患者中冠状动脉疾病、充血性心力衰竭和糖尿病的患病率。对这些患者,研究了按抗高血压药物类别划分的治疗模式。对于所有VA设施,1995年最常处方的10种抗高血压药物中,有4种是钙拮抗剂,2种是血管紧张素转换酶(ACE)抑制剂,2种是β受体阻滞剂,2种是利尿剂。1996年,由于增加了一种ACE抑制剂并减去了一种利尿剂组合,情况发生了变化。钙拮抗剂在1995年占治疗天数的37%,1996年占35%,ACE抑制剂的使用从34%增至36%,β受体阻滞剂从17%增至18%,利尿剂的使用保持在12%。1996年,在钙拮抗剂上花费了约86,600,000美元,在ACE抑制剂上花费了51,800,000美元,在β受体阻滞剂上花费了7,900,000美元,在利尿剂上花费了3,600,000美元。钙拮抗剂每1%转换为β受体阻滞剂的估计年度成本节省为713,000美元,转换为利尿剂为758,000美元。在7526名患有已知合并症的高血压患者子集中,钙拮抗剂和ACE抑制剂也是所有类别患者(包括无冠状动脉疾病、充血性心力衰竭和糖尿病的患者)最常用的药物类别。钙拮抗剂和ACE抑制剂是1995年和1996年VA设施中最常配发的抗高血压药物,从1995年到1996年钙拮抗剂的使用略有下降。与主要使用利尿剂和β受体阻滞剂相比,这些实践模式的成本影响巨大。